We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
42 hedge funds and large institutions have $4.51M invested in ImmunoCellular Therapeutics, Ltd. in 2014 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
17% more funds holding
Funds holding: 36 → 42 (+6)
3% less capital invested
Capital invested by funds: $4.66M → $4.51M (-$151K)
13% less call options, than puts
Call options by funds: $121K | Put options by funds: $139K
Holders
42
Holders Change
+6
Holders Change %
+16.67%
% of All Funds
1.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
6
Closed
2
Calls
$121K
Puts
$139K
Net Calls
-$18K
Net Calls Change
-$45K
Top Buyers
| 1 |
CC
Callan Capital
La Jolla,
California
|
+$391K |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
+$252K |
| 3 |
Morgan Stanley
New York
|
+$131K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$60.7K |
| 5 |
Citigroup
New York
|
+$31.7K |
Top Sellers
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$691K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$35.4K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$12.2K |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$11.7K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.75K |
